Tatsumi M; Groshan K; Blakely RD; Richelson E (1997). «Pharmacological Profile of Antidepressants and Related Compounds at Human Monoamine Transporters.». Eur J Pharmacol.340 (2–3): 249-258. PMID9537821. doi:10.1016/S0014-2999(97)01393-9.
Sussman N; Ginsberg DL; Bikoff J (abril de 2001). «Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials». The Journal of Clinical Psychiatry62 (4): 256-60. PMID11379839. doi:10.4088/JCP.v62n0407.
Mylecharane EJ (1991). «5-HT2 receptor antagonists and migraine therapy». J. Neurol.238 (Suppl 1): S45-52. PMID2045831. doi:10.1007/BF01642906.
Millan MJ (2005). «Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies». Therapie60 (5): 441-60. PMID16433010. doi:10.2515/therapie:2005065.
Tatsumi M; Groshan K; Blakely RD; Richelson E (1997). «Pharmacological Profile of Antidepressants and Related Compounds at Human Monoamine Transporters.». Eur J Pharmacol.340 (2–3): 249-258. PMID9537821. doi:10.1016/S0014-2999(97)01393-9.
Sussman N; Ginsberg DL; Bikoff J (abril de 2001). «Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials». The Journal of Clinical Psychiatry62 (4): 256-60. PMID11379839. doi:10.4088/JCP.v62n0407.
Mylecharane EJ (1991). «5-HT2 receptor antagonists and migraine therapy». J. Neurol.238 (Suppl 1): S45-52. PMID2045831. doi:10.1007/BF01642906.
Millan MJ (2005). «Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies». Therapie60 (5): 441-60. PMID16433010. doi:10.2515/therapie:2005065.